Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
DprE1(FAD-dependent decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase) | 1 |
Target |
Mechanism DprE1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Bacterial growth inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Oct 2021 |
Sponsor / Collaborator |
Start Date07 Jun 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BTZ-043 ( DprE1 ) | Pulmonary Tuberculosis More | Phase 2 |
HKI 9924155 | Bacterial Infections More | Pending |
HKI 9924154 | Gram-Negative Bacterial Infections More | Pending |